Advertisement

Picture Berlin Partner Top News CareSyntax Raises $61m for Bio Cheese 650x100px
Document › Details

Galapagos N.V.. (1/8/19). "Press Release: Sands Capital Reports 5.7% Holding in Galapagos". Mechelen.

Organisations Organisation Galapagos N.V. (Euronext + Nasdaq: GLPG)
  Group Galapagos (Group)
  Organisation 2 Sands Capital Management LLC
Products Product drug discovery
  Product 2 finance
Index term Index term Galapagos–Sands Capital: investment, 201901 investment existent Sands Capital Management LLC owns 3.1m ADSs = 5.7% shareholding
Persons Person Goodwin, Elizabeth (Galapagos 201112 Director Investor Relations)
  Person 2 Van Gijsel, Sofie (Galapagos 201812 Director IR)
     


Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Sands Capital Management, LLC.

Pursuant to Belgian transparency legislation[1], Galapagos received a transparency notification on 27 December 2018 from Sands Capital Management, LLC, who notified that it held 3,092,264 of Galapagos' voting securities (consisting of American Depository Shares) on 13 September 2018. On this date, Sands Capital Management, LLC, crossed the 5% threshold of Galapagos' voting securities by acquiring additional securities. These 3,092,264 securities represented 6.02% of Galapagos' then outstanding 51,337,763 shares. Since the number of outstanding Galapagos shares currently stands at 54,465,421, the 3,092,264 securities of Sands Capital Management currently represent 5.7%. The full transparency notice is available on the Galapagos website.


About Galapagos

Galapagos (Euronext & NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, osteoarthritis and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.

Contact

Investors:
Elizabeth Goodwin
VP IR & Corporate Communications
+1 781 460 1784

Sofie Van Gijsel
Director IR
+32 485 19 14 15
ir@glpg.com

Media:
Evelyn Fox
Director Communications
+31 6 53 591 999
communications@glpg.com


[1] Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market.

   
Record changed: 2023-06-05

Advertisement

Picture Berlin Partner Voices Tim Huse BIH Digital Health 650x200px

More documents for Galapagos (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2024 Stockholm from 14 Sep 650x300px




» top